<DOC>
	<DOCNO>NCT00901147</DOCNO>
	<brief_summary>The purpose study determine whether intravenous Bortezomib combine oral Panobinostat ( LBH589 ) effective treat adult patient relapsed/refractory peripheral T-cell lymphoma NK/T-cell lymphoma failure conventional chemotherapy .</brief_summary>
	<brief_title>Study Bortezomib Panobinostat Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma NK/T-cell Lymphoma</brief_title>
	<detailed_description>Peripheral T-cell lymphoma ( PTCL ) NK/T-cell lymphoma uncommon diseases prevalent Asia . They associate poor prognosis treat conventional chemotherapeutic regime . Their long term disease-free survival dismal 10-30 % patient survive long term . More intensive regimen include high dose chemotherapy autologous stem cell transplant try primary induction treatment , show beneficial . Given rarity PTCL NK/T-cell lymphoma , much literature consist study small sample size anecdotal case report . Therefore , consensus exist best therapeutic strategy either newly diagnose relapsed disease . The failure conventional chemotherapy regard suggest novel therapy include epigenetic approach proteasome inhibition explore . Preclinical data bortezomib histone deacetylase inhibitor ( HDIs ) T-cell NK/T-cell lymphoma cell line encourage . Bortezomib HDIs also separately demonstrated activity T NK/T-cell lymphoma phase II study , lead separate development phase III study . Demonstration synergism 2 agent , part due dependence overlap pathway , suggest explored combination , especially treat disease unfavourable outcome . The purpose phase II study ass efficacy orally-administered panobinostat , potent class I/II pan-deacetylase inhibitor intravenous bortezomib patient population .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Enteropathy-Associated T-Cell Lymphoma</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Histologically confirm PTCL NOS , angioimmunoblastic Tcell lymphoma , extranodal NK/Tcell lymphoma nasal type , enteropathy type Tcell lymphoma , hepatosplenic Tcell lymphoma , ALCL ( ALK1 negative ) , patient ALK 1 express ALCL ( ALK1 positive ) relapse disease ASCT Age ≥21 year Written inform consent Progressive disease follow least one systemic therapy refractory least one prior systemic therapy Measurable disease accord IWC criterion and/or measurable bone marrow disease flow cytometry morphology Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Absolute neutrophil count ≥1000 × 10 ( 9 ) cells/L Serum potassium ≥3.8 mmol/L magnesium ≥0.85 mmol/L ( electrolyte abnormality correct supplementation meet inclusion criterion ) Negative urine serum pregnancy test female childbearing potential All female childbearing potential male must use effective barrier method contraception treatment period least 1 month thereafter . Chemotherapy immunotherapy within 3 week study entry Concomitant use anticancer therapy Concomitant use investigational agent Any known cardiac abnormality : Congenital long QT syndrome ; QTcF interval &gt; 480 millisecond ( msec ) ; A myocardial infarction within 12 month study entry ; Other significant ECG abnormality include 2nd atrioventricular ( AV ) block type II , 3rd degree AV block , bradycardia ( ventricular rate &lt; 50 beats/ min ) . An ECG record screen show significant ST depression ( ST depression ≥2 mm , measure isoelectric line ST segment point 60 msec end QRS complex ) . If doubt , patient stress image study , abnormal , angiography define whether CAD present ; Congestive heart failure ( CHF ) meet New York Heart Association ( NYHA ) Class II IV definition and/or ejection fraction &lt; 40 % MUGA scan &lt; 50 % echocardiogram and/or MRI ; A known history sustain ventricular tachycardia ( VT ) , ventricular fibrillation ( VF ) , Torsade de Pointes , cardiac arrest unless currently address automatic implantable cardioverter defibrillator ( AICD ) ; Hypertrophic cardiomyopathy restrictive cardiomyopathy prior treatment cause ( doubt , see ejection fraction criterion ) ; Any cardiac arrhythmia require antiarrhythmic medication ; Serum potassium &lt; 3.8 mmol/L serum magnesium &lt; 0.85 mmol/L ( electrolyte abnormality correct supplementation meet inclusion criterion ) Concomitant use drug may cause prolongation QTcF Concomitant use CYP3A4 inhibitor Impaired liver , renal organ function cause lymphoma , interfere treatment schedule Concomitant use warfarin due potential drug interaction Clinically significant active infection Known infection human immunodeficiency virus ( HIV ) Patient know clinically active hepatitis B C Previous extensive radiotherapy involve ≥30 % bone marrow ( e.g. , whole pelvis , half spine ) , exclude patient total body irradiation part condition regimen stem cell transplant Major surgery within 2 week study entry Peripheral neuropathy neuropathic pain Grade 2 bad Platelet count &lt; 50 × 109 cells/L platelet count &lt; 30 × 109 cells/L bone marrow disease involvement document Serum creatinine &gt; 2.0 × ULN Patients pregnant breastfeeding Patient know hypersensitivity component bortezomib ( boron , mannitol ) , panobinostat</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>t-cell lymphoma</keyword>
	<keyword>peripheral t-cell lymphoma</keyword>
	<keyword>nk/t-cell lymphoma , nasal type</keyword>
	<keyword>bortezomib</keyword>
	<keyword>velcade</keyword>
	<keyword>panobinostat</keyword>
	<keyword>LBH589b</keyword>
	<keyword>histone deacetylase inhibitor</keyword>
	<keyword>proteasome inhibitor</keyword>
</DOC>